Valence 標誌
熱門
登入

加入到自選清單
專業圖表

Grifols S.A.

NasdaqGS: GRFS · 即時價格 · USD
7.78
-0.15 (-1.89%)
收盤時： Aug 14, 2026, 3:59 PM
7.78
+0.00%
盤後: 4:10 PM

Grifols S.A. (GRFS) Stock Price, Analysis & Data

-1.89%
買價6.78
市值5.29B
營收 (ttm)7.42B
淨利（ttm）452M
貝塔1.19
EPS (ttm)0.75
本益比（ttm）10.37
正向 PE5.46
P/B (ttm)1.66
P/S (ttm)0.71
Earnings DateFeb 25, 2027
賣價8.93
成交量256,699
20 日平均成交量677,462
打開7.92
上一頁關閉7.93
日間範圍7.76 - 7.96
52 週範圍6.96 - 10.65
分析師Buy
目標價10.87 (39.72%)
股利$0.28 (3.55%)
Ex-股利日期2026年7月2日

關於GRFS

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurol...

[閱讀更多]
工業 Drug Manufacturers - General
部門 Healthcare
IPO 日期 Jun 2, 2011
員工 25,258
證券交易所 NasdaqGS
股票代號 GRFS
網站 https://www.grifols.com
完整的公司簡介

財務表現

Grifols S.A. 在 2025 年的營收為 7.52B，較前一年的 7.21B 增加 4.33%。 淨利為 402M，較前期增加 156.05%。

財務報表

分析師預測

根據2 分析師評等，GRFS股票的平均評等為「Buy」。 12個月股價預測為10.87，與最新價格相比為上漲空間的39.72%。

股票預測

獲利驚喜

Grifols S.A. 已於 Jul 28, 2025 公布季度財報：
  • 營收的 $1.87B 錯過估計 $0, 與 4.93% YoY 成長.
  • EPS 的 0.22 錯過估計 -0.06, 與 -24.14% YoY 下降.

    • 下次財報發布

    Grifols S.A. 定於發布財報 Feb 25, 2027, 在​​市場交易時間內。
    分析師預估營收 ... 升級
    news image

    1 週 前 · MT Newswires

    European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday Trading

    European equities traded in the US as American depositary receipts were edging higher late Wednesday

    news image

    2 週 前 · Motley Fool

    Grifols (GRFS) Q2 2026 Earnings Call Transcript

    CEO Abia discusses immunoglobulin growth and Egypt plasma expansion strategy.

    news image

    2 週 前 · GuruFocus.com

    Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ...

    Grifols SA (GRFS) reports robust revenue growth and strategic progress, despite facing temporary challenges in key markets.

    news image

    2 週 前 · MarketBeat

    Grifols Q2 Earnings Call Highlights

    Grifols (NASDAQ:GRFS) said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, i...

    news image

    2 週 前 · Simply Wall St.

    Grifols (BME:GRF) Starts Phase 3 Trials As Undervalued Narrative Faces A Fresh Test

    Grifols (BME:GRF) has started dosing patients in two Phase 3 trials for its immunoglobulin therapies, GAMUNEX-C and XEMBIFY, aiming to expand their U.S. labels and potentially broaden future treatment...

    第 1 頁，共 2 頁